Study confirms link between angio contrast and long-term kidney damage

Jun 24, 2009

The use of x-ray contrast media in patients with kidney impairment can result in higher rates of long-term adverse events such as death, heart attack, and stroke, and different contrast agents can have varying adverse event rates, according to a study published online today in the Clinical Journal of the American Society of Nephrology.

Click here to read the rest of the article.

Latest in Cardiac Imaging
Img 2757
ASTRO: STAR has role in managing VT in cardiac patients
October 1, 2025
Heart Glowing Red
Biograph and Caristo advance coronary inflammation study in U.S.
October 1, 2025
Digital Innovations Shaping the Future of Radiology
Sponsored
Digital Innovations Shaping the Future of Radiology
September 24, 2025
Heart Glowing Red
HeartFlow secures 510(k) for next-gen algorithm
September 23, 2025
Related Stories
2009 06 16 13 49 46 287 2009 06 17 Le Meunier Cardiac Pet Thumb
Nuclear Medicine
High-definition PET improves cardiac studies
2009 05 27 17 19 18 818 Marketstat 56
Digital X-Ray
MarketStat #56: Cath lab sites with fixed cath labs
2009 05 01 14 15 00 257 2009 04 Xx Sterzikchart Thumb
Digital X-Ray
Higher skin radiation dose seen in angiography vs. coronary CTA
Digital Innovations Shaping the Future of Radiology
Sponsor Content
Digital Innovations Shaping the Future of Radiology
More in Cardiac Imaging
ASTRO: STAR has role in managing VT in cardiac patients
By Amerigo Allegretto
Stereotactic arrhythmia radiotherapy (STAR) is safe and effective for treating refractory VT compared to repeat catheter ablation.
October 1, 2025
Img 2757
Biograph and Caristo advance coronary inflammation study in U.S.
By AuntMinnie.com staff writers
The research will evaluate whether coronary inflammation alongside plaque characterization can detect early heart disease.
October 1, 2025
Heart Glowing Red
Cleerly highlights coverage decision effective October 1
By AuntMinnie.com staff writers
Cleerly's AI-QCT software for cardiovascular imaging will be eligible for reimbursement from UnitedHealthcare and Cigna on October 1.
September 30, 2025
Insurance Claim Reimbursement Vinnstock
HeartFlow secures 510(k) for next-gen algorithm
By AuntMinnie.com staff writers
Corresponding with the FDA clearance, the company also highlighted the unveiling of its DECIDE Registry.
September 23, 2025
Heart Glowing Red
Tempus AI secures 510(k) for Pixel
By AuntMinnie.com staff writers
The update reflects new software functionality designed for a comprehensive view of heart tissue.
September 12, 2025
Cardiac Heart Eeg Social (1)
Low-dose CT ties emphysema to mortality in previous smokers
By Amerigo Allegretto
Study findings highlight the clinical relevance of CT-diagnosed emphysema.
September 9, 2025
Representative axial images of mild, moderate, and severe emphysema at baseline low-dose CT (LDCT). Participants were categorized as having no emphysema or mild, moderate, or severe emphysema. When present, emphysema was mild if no distinct regions of reduced attenuation were visible on the CT scan, but vascular splaying indicates parenchymal expansion, or if only occasional discrete low-attenuation regions were observed. Moderate emphysema was defined by the presence of identifiable low-attenuation regions affecting less than half of the lung parenchyma, whereas severe emphysema was defined by the presence of identifiable low-attenuation regions that involved more than half of the lung parenchyma. A scoring system from 0 to 3 was applied, corresponding to none, mild, moderate, and severe emphysema, respectively. Yellow circle indicates the extent of emphysema. (A) A 67-year-old man with mild emphysema at baseline LDCT in 2002. Baseline LDCT scan shows vascular splaying, suggesting parenchymal expansion due to emphysema and occasional discrete low-attenuation regions. The participant ultimately died of cardiovascular disease 15.4 years (184.2 months) later. (B) A 69-year-old man with moderate emphysema at baseline LDCT in 2007. The participant died of cardiovascular disease 1.8 years (21.9 months) later. Identifiable low-attenuation regions affected less than half of the lung parenchyma. (C) An 85-year-old woman with severe emphysema at baseline LDCT in 2006. After 5.5 years (65.5 months) of follow-up, the participant died due to chronic obstructive pulmonary disease–related causes. Identifiable low-attenuation regions involved more than half of the lung parenchyma.
eMyosound to start cardiac ultrasound trial in 3 Boston hospitals
By AuntMinnie.com staff writers
The trial will validate eMyosound technology for the quantitative assessment of myocardial stiffness in patients with heart failure.
September 8, 2025
Heart Ultrasound Adobe Peakstock
GE HealthCare unveils AI-loaded cardiovascular ultrasound system
By AuntMinnie.com staff writers
Adaptive cardiovascular ultrasound system redesigned for 2D, 4D, and color flow imaging.
August 29, 2025
Ge Healthcare Logo 8uqm Sjnztb
Echo images show consequences of steroid use among athletes
By Amerigo Allegretto
Echocardiography shows how anabolic steroid use among athletes impacts heart health.
August 29, 2025
Athlete Runner Chest Pain
DESKi launches cardiac AI software
By AuntMinnie.com staff writers
The software has been integrated into Butterfly Network’s handheld ultrasound devices.
August 27, 2025
Echocardiography
Philips cardiology snapshot highlights challenges for patient care, trust in AI
By AuntMinnie.com staff writers
Royal Philips shared findings from its Future Health Index cardiology snapshot that show challenges in cardiac care and AI.
August 26, 2025
Philips Rsna 2019 400
Esaote lands FDA clearance for two new MyLab ultrasound systems
By AuntMinnie.com staff writers
Esaote has received U.S. Food and Drug Administration (FDA) clearance to market its MyLab A50 and MyLab A70 ultrasound systems.
August 22, 2025
MyLab A70 ultrasound system.
Page 1 of 323
Next Page